Sonthalia Sidharth, Aggarwal Parul
Medical Director and Senior Consultant Dermatologist, Department of Dermatology and Dermatosurgery, Skinnocence: The Skin Clinic and Research Center, Gurugram, Haryana, India.
Consultant Dermatologist, Department of Dermatology and STD, Skinalive Clinic, New Delhi, India.
Indian Dermatol Online J. 2019 Aug 28;10(5):503-518. doi: 10.4103/idoj.IDOJ_474_18. eCollection 2019 Sep-Oct.
Tofacitinib, an oral Janus kinase inhibitor (Jakinib), is an emerging treatment modality whose well-established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders (arising due to the patient's dysimmune responses) that are not responding to and/or sustaining intolerable adverse effects with the classical immunosuppressives and other targeted therapies such as the biologics. The most common dermatoses for which oral as well as topical Jakinibs such as tofacitinib have been evaluated and are being used albeit as an off-label indication include psoriasis, psoriatic arthritis, alopecia areata, vitiligo, and atopic dermatitis. This article provides a succinct review on the current status of oral tofacitinib in dermatology through literature search of PubMed database and stresses on the need for further evidence generation to define the drug's place in the therapeutic arsenal of dysimmune cutaneous disorders.
托法替布是一种口服的Janus激酶抑制剂（Jakinib），是一种新兴的治疗方式。其在全身性炎症性疾病中已确立的疗效，目前正被积极探索用于对经典免疫抑制剂和其他靶向疗法（如生物制剂）无反应和/或持续出现无法耐受的不良反应的皮肤疾病（由患者免疫反应失调引起）。已对口服以及外用的Jakinibs（如托法替布）进行评估并正在使用（尽管属于超适应症用药）的最常见皮肤病包括银屑病、银屑病关节炎、斑秃、白癜风和特应性皮炎。本文通过检索PubMed数据库对口服托法替布在皮肤科的现状进行了简要综述，并强调需要进一步提供证据，以明确该药物在免疫失调性皮肤疾病治疗手段中的地位。
